CD8A and melanoma: Cellular make-up of solid and metastatic tumours (including melanoma) revealed a significantly elevated CD8+ CTL/Treg ratio followed by tumour growth delay and improved survival rate as a consequence of combined treatment with RT and Ipilimumab or RT and Nivolumab/Pembrolizumab [70,71].